Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Inflation Reduction Act (IRA) boosts biological drugs

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 19, 2024 10:49am

80 Views

Post# 35940523

RE:RE:RE:RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

Measures are being taken by the EU to reduce their dependency on Chinese for small molecules (synthetic APIs and raw materials), and is taking strategic steps towards self-reliance after the US- China trade war and the Covid-19 outbreak.

https://www.beroeinc.com/whitepaper/china-current-state-small-molecule-synthetic-api-market/#:~:text=The%20small%2Dmolecule%20synthetic%20API,the%20value%20chain%20is%20difficult.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant